Decitabine for injection
Indication
It is suitable for the first-time and retreatment of intermediate-2 and high-risk myelodysplastic syndrome (MDS) in the IPSS scoring system, including primary and secondary MDS, and all subtypes according to the FAB classification.
Packaging Specification
50mg
Manufacturer
Zhengda Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
-
Founded in:
2013-04-22 -
Address:
No. 1099, Fuying Road, Jiangning District, Nanjing (Jiangning High-tech Park) -
Tax NO.:
913201150670551106 -
Registered Funds:
500 million yuan -
Email: